MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
More news: Health / Surgery
Written by / Agency / Source: Advanced Cell Technology, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

First Clinical Trial Against Macular Degeneration by Advanced Cell Technology - Advanced Cell Technology receives FDA clearance for the first clinical trial using embryonic stem cells to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world
First Clinical Trial Against Macular Degeneration by Advanced Cell Technology

 

NewswireToday - /newswire/ - Santa Monica, CA, United States, 2010/11/25 - Advanced Cell Technology receives FDA clearance for the first clinical trial using embryonic stem cells to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC) announced today that the US Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt's Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.

Stargardt's Macular Dystrophy causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium (RPE). . "There is currently no treatment for Stargardt's disease," said Dr. Robert Lanza, ACT's Chief Scientific Officer. "Using stem cells, we can generate a virtually unlimited supply of healthy RPE cells, which are the first cells to die off in SMD and other forms of macular degeneration. We've tested these cells in animal models of eye disease. In rats, we've seen 100% improvement in visual performance over untreated animals without any adverse effects. Our studies showed that the cells were capable of extensive rescue of photoreceptors in animals that otherwise would have gone blind. Near-normal function was also achieved in a mouse model of Stargardt's disease. We hope to see a similar benefit in patients with various forms of macular degeneration."

The Phase I/II trial will be a prospective, open-label study that is designed to determine the safety and tolerability of the RPE cells following sub-retinal transplantation to patients with advanced SMD. A total of twelve patients will be enrolled in the study at multiple clinical sites. The sites which are currently under consideration are the Jules Stein Eye Institute at UCLA (headed by Dr. Steven Schwartz); the Casey Eye Institute in Portland, Oregon (headed by Dr. Peter Francis of the Oregon Health Sciences University); the University of Massachusetts Memorial Medical Center in Worcester, Massachusetts (headed by Dr. Shalesh Kaushal, Chair of the Department of Ophthalmology); the UMDNJ – New Jersey Medical School in Newark, New Jersey (headed by Dr. Marco Zarbin, Chair, Institute of Ophthalmology and Visual Science); additional sites may be considered.

Earlier this year the FDA also granted Orphan Drug designation for the company's RPE cells. As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials such as this one, accelerated FDA approval, and allowance for marketing exclusivity after drug approval for a period of as long as seven years.

Raymond Lund, Ph.D., a scientific collaborator with ACT, and considered one of the world's foremost experts in retinal cell physiology and vision restoration, commented, "The study results of ACT's RPE cells implanted in the various animal models of macular degeneration was phenomenal. If ACT observes even a fraction of that benefit in humans, it will be nothing short of a home run."

"Initiating our macular degeneration clinical trial represents a significant milestone in the progress of developing human embryonic stem cell-based therapies aimed at large worldwide markets," said William M. Caldwell IV, ACT's Chairman and CEO. "I think generations will look back at this time as one of the most exciting in the history of medicine. With the initiation of this clinical trial, and that of Geron’s earlier this fall, the field of regenerative medicine is poised to take embryonic stem cell therapies from the realm of nebulous potential to that of tangible and real treatments that will make a significant difference in the lives of millions of people worldwide. This is truly a 'game changer' for the medical community."

Among the most common causes of untreatable blindness in the world are degenerative diseases of the retina. As many as thirty million people in the United States and Europe suffer from macular degeneration, which represents a $25-30 billion worldwide market that has yet to be effectively addressed. Approximately 10% of people ages 66 to 74 will have symptoms of macular degeneration, the vast majority the "dry" form of AMD – which is currently untreatable. The prevalence increases to 30% in patients 75 to 85 years of age.

"These patient numbers are staggering in size," stated Edmund Mickunas, ACT's Vice President of Regulatory, "and when the impact on health and quality-of-life is considered in that context, macular degeneration represents one of the more significant unmet medical needs in our society. With the momentum of this Stargardt's trial, and the unique experience we have gained as one of the few companies in the world having succeeded in taking an hESC program into the clinic, we are preparing to extend our lead with an IND in the use for treating age-related macular degeneration, as well as filing to begin clinical trials in Europe, in the very near future."

About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. (advancedcell.com) is a biotechnology company applying cellular technology in the field of regenerative medicine.

Forward-Looking Statements:
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2009. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Advanced Cell Technology, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health / Surgery articles,
CATCH Visitors via Your Competitors Announcements!


First Clinical Trial Against Macular Degeneration by Advanced Cell Technology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Nicholas Wade - AdvancedCell.com 
310-576-0611 press[.]advancedcell.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Advanced Cell Technology, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Health / Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Advanced Cell Technology, Inc. / Company Profile


Read Health / Surgery Most Recent Related Newswires:

Inkwood Research Publishes Global Genetic Testing Market Forecast 2019-2027
NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines
Alopecia Hair Loss Treatment Market is Advancing At A CAGR of 5.51% by 2027 According to Inkwood Research
Frost & Sullivan Distinguishes Inovalon as Company of the Year for Advancing the Healthcare Industry by Harnessing Massive-Scale Data
South Carolina Life Sciences Industry Honors USC’s Dr. Harris Pastides, AVX Corporation
Neurodegenerative Disorder Therapeutics Market Sees a Silver Lining with Cell and Gene Therapies Finds Frost & Sullivan
Medisanté Earns Acclaim from Frost & Sullivan for Ensuring Better Care Outcomes while Reducing Costs
The Global Postpartum Hemorrhage Treatment Device Market is Estimated to Grow At 5.10% CAGR by 2027 Finds Inkwood Research
Digital Health to Empower Women and Aging Population with mHealth, Telemedicine, Femtech and AI Finds Frost & Sullivan
Technological Advancements Propels the Global Healthcare Analytics Market At 27.13% CAGR by 2027 Reports Inkwood Research
SC Life Sciences Conference to Feature J&J Innovation Leader Michal Preminger, 40 National Speakers
American Well® Applauded by Frost & Sullivan for Driving Telehealth’s Next Growth Wave with its Pioneering Strategy
Liquid Biopsy Applications Drives the Global DNA Sequencing Market At a CAGR of 17.46% by 2027 Finds Inkwood Research
The Growing Geriatric Population Propels the Global Diabetes Drugs Market At A CAGR of 6.50%, 2027 Finds Inkwood Research
Technological Development are Driving the Global Dental Imaging Market at a CAGR of 8.38% by 2027 Finds Inkwood Research

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Inkwood Research

Visit Havens Metal Works





 
  ©2019 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)